BackAmylyx Pharmaceuticals Overview

Amylyx Pharmaceuticals Receivables

Latest receivables for AMLX: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00
↓ 100.00% YoYΔ $-300000.00 vs prior year quarter

Peer average

Loading

Amylyx Pharmaceuticals Receivables History

Loading

Amylyx Pharmaceuticals vs. peers: Receivables Comparison

Loading

Amylyx Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Amylyx Pharmaceuticals (AMLX) FAQ

The latest receivables for AMLX is $0 as of March 2026. That compares with $300K in the prior-year period — down 100.0% year over year. Investors often review this figure alongside Amylyx Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, AMLX's receivables moved from $300K to $0 — a 100.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Amylyx Pharmaceuticals's operating scale or balance-sheet position.

A receivables figure of $0 for AMLX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AMLX's receivables ($0), review year-over-year change from $300K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.